166 related articles for article (PubMed ID: 17671841)
1. P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.
Jeczen R; Skomra D; Cybulski M; Schneider-Stock R; Szewczuk W; Roessner A; Rechberger T; Semczuk A
Clin Exp Metastasis; 2007; 24(7):503-11. PubMed ID: 17671841
[TBL] [Abstract][Full Text] [Related]
2. The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations.
Olcha P; Cybulski M; Skomra D; Obrzut B; Ignatov A; Jóźwik M; Schneider-Stock R; Semczuk A
Int J Gynecol Cancer; 2010 Aug; 20(6):993-9. PubMed ID: 20683407
[TBL] [Abstract][Full Text] [Related]
3. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.
Soslow RA; Shen PU; Chung MH; Isacson C
Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809
[TBL] [Abstract][Full Text] [Related]
4. Allelic loss at TP53 in metastatic human endometrial carcinomas.
Szewczuk W; Skomra D; Cybulski M; Przadka-Rabaniuk D; Filip A; Jóźwik M; Olcha P; Roessner A; Semczuk A
Clin Exp Metastasis; 2009; 26(7):789-96. PubMed ID: 19565339
[TBL] [Abstract][Full Text] [Related]
5. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome.
Lobo J; Alzamora MA; Guimarães R; Cantante M; Lopes P; Braga I; Maurício J; Jerónimo C; Henrique R
Andrology; 2020 Sep; 8(5):1233-1242. PubMed ID: 32384200
[TBL] [Abstract][Full Text] [Related]
6. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
[TBL] [Abstract][Full Text] [Related]
7. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
8. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
9. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
[TBL] [Abstract][Full Text] [Related]
10. Nicotinamide N-methyltransferase expression and its association with phospho-Akt, p53 expression, and survival in high-grade endometrial cancer.
Akar S; Harmankaya İ; Uğraş S; Çelik Ç
Turk J Med Sci; 2019 Oct; 49(5):1547-1554. PubMed ID: 31652035
[TBL] [Abstract][Full Text] [Related]
11. P53 and Murine Double Mimute 2 (MDM2) Expression Changes and Significance in Different Types of Endometrial Lesions.
Jiang Z; Xu W; Dan G; Liu Y; Xiong J
Med Sci Monit; 2016 Dec; 22():4786-4793. PubMed ID: 27924072
[TBL] [Abstract][Full Text] [Related]
12. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
15. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
16. CP‑31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating MDM2 expression.
Liu L; Yang L; Chang H; Chen YN; Zhang F; Feng S; Peng J; Ren CC; Zhang XA
Int J Oncol; 2019 Mar; 54(3):942-954. PubMed ID: 30628640
[TBL] [Abstract][Full Text] [Related]
17. Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia.
Buchynska LG; Nesina IP; Kashuba EV
Exp Oncol; 2007 Dec; 29(4):287-94. PubMed ID: 18199985
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
[TBL] [Abstract][Full Text] [Related]
20. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival.
Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A
Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]